SOPHiA GENETICS announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM? Platform to support research on homologous recombination repair (HRR) biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers.

Città della Salute e della Scienza di Torino is part of one of the largest university hospitals and health systems in Europe. As such, the institution cares for thousands of people each year and is responsible for the efficient, accurate and secure analysis of a vast amount of genomic data. NGS is helping to revolutionize the research of several cancers and rare diseases, yet it yields extremely large and complex datasets for analysis.

The Microsoft Azure-powered SOPHiA DDM? Platform uses artificial intelligence and machine learning with patented technologies to streamline the analysis of raw NGS data and generate biologically actionable insights, which can speed the research process and ultimately lead to better health outcomes. SOPHiA GENETICS has worked with Microsoft to further the democratization of data-driven medicine. Using the secure, cloud-based infrastructure of Microsoft Azure, SOPHiA GENETICS offers a solution via the SOPHiA DDM?

Platform that helps break the data silos and facilitate data-sharing and research advancements.